Literature DB >> 32575853

An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System.

Claudiu Morgovan1, Smaranda Adina Cosma2, Madalina Valeanu3, Anca Maria Juncan1, Luca Liviu Rus1, Felicia Gabriela Gligor1, Anca Butuca1, Delia Mirela Tit4, Simona Bungau4, Steliana Ghibu5.   

Abstract

The prevalence of diabetes mellitus (DM) rises constantly each year worldwide. Because of that, the funds allocated for the DM treatment have increased over time. Regarding the number of DM cases, Romania is among the top ten countries in Europe. Based on the National Diabetes Programme (NDP), antidiabetic drugs and other expenditures (Self-monitoring blood glucose (SMBG) test, HbA1c, insulin pumps/insulin pumps supplies) are free of charge. This programme has undergone many changes in drugs supply, in the last two decades: re-organizing the NDP, authorization of new molecules with high prices (e.g., SGLT-2 inhibitors, etc.) or new devices (e.g., insulin pumps, etc.) The main purpose of this study is to identify and analyse the impact of the DM costs on the Romanian health budget and to highlight the evolution of these costs. A retrospective longitudinal research on the official data regarding the DM costs from 2000 to 2017 was performed. The DM funds (DMF) were adjusted with the inflation rate. In this period, the average share of DMF in the total funds allocated for health programmes was 21.3 ± 3.4%, and DMF average growth rate was 25.4% (r = 0.488, p = 0.047). On the other hand, the DMF increased more than 14 times, in spite of the patients' number having increased only about 2.5 times. Referring to the structure of DMF, the mean value of the antidiabetic drugs cost was of 96,045 ± 67,889 thousand EUR while for other expenditures it was of 11,530 ± 7922 thousand EUR (r = 0.945, p < 0.001). Between 2008 and 2017, the total DMF was 181,252 ± 74,278 thousand EUR/year. Moreover, the average patients' number was 667,384 ± 94,938 (r = 0.73, p = 0.016), and the cost of treatment was 215 ± 36 EUR/patient/year. Even if the cost is rising, the correct and optimal treatment is a main condition for the diabetic patient's health and for the prevention of its complications, which have multiple socio-economic repercussions.

Entities:  

Keywords:  National Diabetes Programme; Romanian National Health Insurance System; antidiabetic drugs; diabetes mellitus cost; efficiency indicators; pharmacoeconomics; physical indicators

Year:  2020        PMID: 32575853     DOI: 10.3390/ijerph17124456

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  6 in total

1.  Hospitalization Costs of Lower Limb Ulcerations and Amputations in Patients with Diabetes in Romania.

Authors:  Diana I Sima; Cosmina I Bondor; Ioan A Vereşiu; Norina A Gâvan; Cristina M Borzan
Journal:  Int J Environ Res Public Health       Date:  2021-02-24       Impact factor: 3.390

2.  Factors Associated with Free Medicine Use in Patients with Hypertension and Diabetes: A 4-Year Longitudinal Study on Full Coverage Policy for Essential Medicines in Taizhou, China.

Authors:  Zhigang Guo; Lin Bai; Zhenhuan Luo; Mengyuan Fu; Liguang Zheng; Xiaodong Guan; Luwen Shi
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

3.  Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China.

Authors:  Qian Xing; Wenxi Tang; Mingyang Li; Shuailong Li
Journal:  Int J Environ Res Public Health       Date:  2022-04-03       Impact factor: 3.390

4.  Impact of Kinesiotherapy and Hydrokinetic Therapy on the Rehabilitation of Balance, Gait and Functional Capacity in Patients with Lower Limb Amputation: A Pilot Study.

Authors:  Vlad-Theodor Cotrobas-Dascalu; Dana Badau; Marius Stoica; Adina Andreea Dreve; Corina Michaela Lorenta Predescu; Carmen Liliana Gherghel; Mircea Bratu; Popescu Raducu; Antoanela Oltean; Adela Badau
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

5.  Length of Hospital Stay, Hospitalization Costs, and Their Drivers in Adults with Diabetes in the Romanian Public Hospital System.

Authors:  Cornelia Bala; Adriana Rusu; Dana Ciobanu; Gabriela Roman
Journal:  Int J Environ Res Public Health       Date:  2022-08-14       Impact factor: 4.614

6.  Clinical, Pathological and Microbiological Evaluation of Diabetic Foot Syndrome.

Authors:  Bogdan Uivaraseanu; Simona Bungau; Delia Mirela Tit; Ovidiu Fratila; Marius Rus; Teodor Andrei Maghiar; Octavian Maghiar; Carmen Pantis; Cosmin Mihai Vesa; Dana Carmen Zaha
Journal:  Medicina (Kaunas)       Date:  2020-07-28       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.